CN1390560A - Orally applied anticancer tablet - Google Patents

Orally applied anticancer tablet Download PDF

Info

Publication number
CN1390560A
CN1390560A CN 01114528 CN01114528A CN1390560A CN 1390560 A CN1390560 A CN 1390560A CN 01114528 CN01114528 CN 01114528 CN 01114528 A CN01114528 A CN 01114528A CN 1390560 A CN1390560 A CN 1390560A
Authority
CN
China
Prior art keywords
orally applied
applied anticancer
anticancer tablet
tablet
raw material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 01114528
Other languages
Chinese (zh)
Inventor
吴戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 01114528 priority Critical patent/CN1390560A/en
Publication of CN1390560A publication Critical patent/CN1390560A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

An anticancer oral tablet for treating liver cancer, lung cancer, stomach cancer, etc is prepared from 8 Chinese-medicinal materials including bitter orange, curcuma root, sodium sulfate, alum, etc through proportioning, extracting liquid and tabletting. Its advantages are sure curative effect and high total remission rate (92.5%).

Description

Orally applied anticancer tablet
The present invention relates to a kind of is the Chinese patent medicine of feedstock production with the Chinese herbal medicine, particularly a kind of Orally applied anticancer tablet.
Cancer is the healthy dangerous diseases of serious harm people, and effectively the medicine of treatment is few at present.Present most of cancer patient is to add by the chemotherapy with doctor trained in Western medicine to take the treatment of Western medicine integrated approach, and curative effect is undesirable, particularly can bring a lot of other slight illness, grievous injury patient body health tissues to patient because of chemotherapy.Current for avoiding other infringement of doctor trained in Western medicine chemotherapy to cancer patient, there are numerous people all from traditional Chinese herbal medicine of China, to seek suitable medicine and prescription consumption in research.Mostly the prescription types of medicines that uses is on the low side, exchanges the body whole functional partner treatment of the giving sb. a hard time part that still has some deficits, and is single with the property of medicine, is more general deficiency, and Comprehensive Treatment is considered incomplete, and curative effect is not high.Chinese patent application numbers 94110126 discloses " a kind of serial Chinese medicine and compound method for the treatment of hepatocarcinoma ", and Chinese patent application numbers 91112645 discloses the manufacture method of treatment new drug " three essentials-essence beneficence pellet ".In their magistral medicines, used animal or its bone to be raw material respectively, some still is a rare animal, and the source difficulty is unsuitable for mass production and adopts.Chinese patent application number 97108264.2 disclosed antitumor oral liquids have very significant curative effect, but also have animal bone in the medication raw material, and the source is rare, and because of being that oral liquid has portably used inconvenience for packing, transportation, patient, thereby it is improved.
The purpose of this invention is to provide a kind of heart tonifying that detoxifies, promoting the circulation of QI pain relieving, be good for the stomach and nourish blood, strengthen the Orally applied anticancer tablet of immune function of human body.
Task of the present invention realizes with the following methods: Orally applied anticancer tablet, its active component is prepared from by following proportion raw material by weight percentage: Fructus Aurantii 20~26, Radix Curcumae 11~17, Natrii Sulfas 10~15, Resina Toxicodendri 0~7, Alumen 11~16, Semen Strychni 6~12, Oletum Trogopterori 10~14, Herba Agrimoniae 11~16.Its active component is prepared from by following proportion raw material by weight percentage: Fructus Aurantii 22, Radix Curcumae 15, Natrii Sulfas 12, Resina Toxicodendri 5, Alumen 13, Semen Strychni 8, Oletum Trogopterori 12, Herba Agrimoniae 13.The steaming and decocting of used main Chinese herbal medicine water, total consumption of Chinese herbal medicine and water consumption weight ratio are 1: (9-11).
The raw material that Orally applied anticancer tablet of the present invention adopts natural Chinese medicinal herb and nature to exist forms through processing and preparing, assault fortified position removing mass, go polyp, erosion rotten in, detoxifcation heart tonifying, promoting the circulation of QI pain relieving, be good for the stomach nourish blood, function such as strengthening vital QI to eliminate pathogenic factors, after taking Orally applied anticancer tablet of the present invention, can make human body increase immunity, resist cancerous cell generation and diffusion, reach therapeutic effect, be suitable for hepatocarcinoma, pulmonary carcinoma, gastric cancer, esophageal carcinoma, osteocarcinoma patient's control is taken.
The used Chinese herbal medicine of the embodiment of the invention is prepared from by following proportion raw material by weight percentage with its active component: Fructus Aurantii 22, Radix Curcumae 15, Natrii Sulfas 12, Resina Toxicodendri 5, Alumen 13, Semen Strychni 8, Oletum Trogopterori 12, Herba Agrimoniae 13.
Think in Chinese medicine: the formation of tumor mainly is that wherein QI and blood pent-up was main due to QI and blood, expectorant, food stagnancy knot gathered, and the expectorant food stagnation is lived in concentrated communities time, between four, interacts, and holds concurrently mutually to sick.
Orally applied anticancer tablet is used for clinical difficulty through hospital, sets up western medicine group to carry out curative effect comparision.Treatment is organized in 280 examples, male's 172 examples, women's 88 examples, and the age is at 30 years old to 70 years old, 55 years old mean age.In matched group 260 examples, male's 190 examples, women's 70 examples, the age is at 37 years old to 66 years old, 55.7 years old mean age.Two groups of patients are the trouble malignant tumor, are the patients who suffers from hepatocarcinoma, pulmonary carcinoma, gastric cancer, esophageal carcinoma, osteocarcinoma.
The treatment group is taken the Orally applied anticancer tablet preparation, and matched group adopts the Western medicine combined chemotherapy.Decide according to patient's the state of an illness course of treatment.Curative effect judging standard divides five kinds: alleviate fully (CR): all visible pathological changes complete obiterations are also kept more than 4 weeks at least; Part is alleviated (PR): the product in tumor focus maximum diameter and maximum perpendicular footpath thereof reduces more than 50%, and more than around keeping; (MR) takes a turn for the better: two footpath products of tumor focus dwindle<and more than 25%, but<50%, no focus appearance; Stable (SD): tumor focus two footpath products are little<and 25%, or increase<25%, do not have new focus and occur; Lesion growth (PD): tumor focus two footpath products increase>25%, or new focus occurs.Therapeutic outcome, treatment group are alleviated fully and are accounted for 38.4%, and part remission rate 41.5% takes a turn for the better and accounts for 10.38%, stablely account for 3.84%, and progress accounts for 5.7%, total remission rate 92.59%.Matched group is alleviated fully and is accounted for 37.6%, and part is alleviated and accounted for 46.1%, takes a turn for the better and accounts for 2.9%, stablely accounts for 4.23%, and progress accounts for 9.23%, total remission rate 81.66%.Treatment group and contrast remission rate have significant difference, it is little that the treatment group has side reaction, rapid-action, medication is convenient, and group can be improved symptom rapidly, dwindle the effect of tumor, medical expense is low by 75%, and the patient is willing to accept good effect, it is not good enough to be particularly useful for body constitution, can not tolerate the older patient of chemotherapy.
The performance of used Chinese herbal medicine is: Fructus Aurantii has circulation of qi promoting removing mass, excited gastrointestinal effect; Radix Curcumae regulates the flow of vital energy, loose become silted up, be good for the stomach, function of gallbladder promoting, diuresis; Natrii Sulfas has purging heat to relax the bowels, moistening for dryness and softening hard mass, quench detumescence effect; Alumen claims Alumen again, for natural alunite refines the crystalline solid that forms through processing, convergence antiinflammatory, antidiarrheal, anastalsis is arranged; Semen Strychni has that excitement is refreshed oneself, detoxifcation, digestion promoting function; Oletum Trogopterori is the dry feces of flying squirrel section animal trogopterus xanthipes, and the effect of eliminating stasis to stop pain is arranged, and cures mainly the pain disease due to the blood stasis; Herba Agrimoniae has hemostasis, heart tonifying, antibacterial action, and it is hemorrhage to be widely used in treatment health each several part; Resina Toxicodendri is Anacardiaceae plant coating resins processing after drying product, and general the collection contained the lacquer slag that stays at the bottom of the lacquerware tool, drying.Its concocting method is to get Resina Toxicodendri, puts fire and go up to burn withered or knock fritter, put fry in the pot to shrivelled black smoke to the greatest extent, take out, cool.Removing blood stasis with potent drugs blood is arranged, removing food stagnancy, insecticidal action.
The preparation technology of this Orally applied anticancer tablet is basic identical with pharmaceutical methods commonly used, the herbal raw material screening is cleaned, again medical material is cut into slices or shred, tentatively sterilize with common method, batching put into add an amount of water water of 10 times of herbal raw material weight (as select for use) in the digester simultaneously and carry out steaming and decocting, cooking pressure 4.5kg/cm 2, digestion time 8 hours is put it into evaporation and concentration in the concentration pan again, with 20%~40% of the concentrated most stock solution of medicinal liquid, through pressure filtration, the filtrate that obtains is used for granulating, again through quality inspection with spissated medicinal liquid, oven dry, but tabletting preparation cost Orally applied anticancer tablet then get final product packed for standby use through quality inspection.

Claims (3)

1. Orally applied anticancer tablet is characterized in that its active component is prepared from by following proportion raw material by weight percentage:
Fructus Aurantii 20~26, Radix Curcumae 11~17, Natrii Sulfas 10~15, Resina Toxicodendri 0~7, Alumen 11~16,
Semen Strychni 6~12, Oletum Trogopterori 10~14, Herba Agrimoniae 11~16.
2. Orally applied anticancer tablet as claimed in claim 1 is characterized in that its active component is prepared from by following proportion raw material by weight percentage: Fructus Aurantii 22, Radix Curcumae 15, Natrii Sulfas 12, Resina Toxicodendri 5, Alumen 13, Semen Strychni 8, Oletum Trogopterori 12, Herba Agrimoniae 13.
3. Orally applied anticancer tablet as claimed in claim 1 is characterized in that the steaming and decocting of used main Chinese herbal medicine water, and total consumption of Chinese herbal medicine and water consumption weight ratio are 1: (9-11).
CN 01114528 2001-06-07 2001-06-07 Orally applied anticancer tablet Pending CN1390560A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 01114528 CN1390560A (en) 2001-06-07 2001-06-07 Orally applied anticancer tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 01114528 CN1390560A (en) 2001-06-07 2001-06-07 Orally applied anticancer tablet

Publications (1)

Publication Number Publication Date
CN1390560A true CN1390560A (en) 2003-01-15

Family

ID=4661166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 01114528 Pending CN1390560A (en) 2001-06-07 2001-06-07 Orally applied anticancer tablet

Country Status (1)

Country Link
CN (1) CN1390560A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103566282A (en) * 2012-07-27 2014-02-12 西安正大制药有限公司 Traditional Chinese medicine composition with anti-tumor effect and preparation method thereof
CN106389872A (en) * 2016-09-26 2017-02-15 魏庆 Traditional Chinese medicine composition for preventing and treating tumors and preparation method of traditional Chinese medicine composition for preventing and treating tumors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103566282A (en) * 2012-07-27 2014-02-12 西安正大制药有限公司 Traditional Chinese medicine composition with anti-tumor effect and preparation method thereof
CN106389872A (en) * 2016-09-26 2017-02-15 魏庆 Traditional Chinese medicine composition for preventing and treating tumors and preparation method of traditional Chinese medicine composition for preventing and treating tumors

Similar Documents

Publication Publication Date Title
CN100435831C (en) Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method
CN1354014A (en) Gongbu ointment
CN101612357B (en) Chinese traditional medicine composition for treating tumor and preparing method thereof
CN102106991A (en) Medicament for treating moderate/advanced liver cancer chemoembolization
CN101612279B (en) Chinese medicine preparation for promoting fracture healing
CN102266052A (en) Health care food with function of improving sleeping
CN101214352B (en) Chinese medicine for treating hyperlipemia
CN100553673C (en) The Chinese patent medicine of treatment chronic pharyngitis
CN1990033A (en) Drug for treating hypertension, dense blood and arteriosclerosis
CN100457169C (en) Medicine for treating chronic colitis and its preparing process
CN1390560A (en) Orally applied anticancer tablet
CN101979035A (en) Medicament for treating gynecological abnormal leucorrhea
CN101869700B (en) Chinese medicinal oral liquid for treating tumour and preparation method thereof
CN104800768B (en) A kind of Chinese medicine composition for treating hypogalactia after delivery
CN1062470C (en) Chinese medicine prepn for infant anorexia
CN107913389A (en) A kind of Chinese medicine composition for treating Thyroid Gland Swell and preparation method thereof
CN110420309B (en) Anti-inflammatory analgesic Tibetan medicine pill for treating chronic appendicitis
CN1072940C (en) Oral liquid for anti-cancer
CN101468144B (en) Chinese medicine compound preparation for treating ventricular premature beat
CN100515463C (en) Oral liquid for treating cancer and preparing method thereof
CN101468149B (en) Quick-effective hypoglycemic Chinese medicine preparation
CN101129691A (en) Angelica decoction for treating hernia
CN100358569C (en) Cancer-treating medicine and its preparation method
CN106236873A (en) A kind of Chinese medicine composition treating disease of stomach
CN105796676A (en) Pills for effectively treating fatty liver

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication